These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

128 related items for PubMed ID: 1700524

  • 1. [Myeloid hemopoietic growth factors. Therapeutic possibilities and clinical experiences].
    Hansen B, Johnsen HE.
    Ugeskr Laeger; 1990 Oct 29; 152(44):3232-7. PubMed ID: 1700524
    [Abstract] [Full Text] [Related]

  • 2. [GM-CSF and G-CSF: cytokines in clinical application].
    Ruef C, Coleman DL.
    Schweiz Med Wochenschr; 1991 Mar 23; 121(12):397-412. PubMed ID: 1709294
    [Abstract] [Full Text] [Related]

  • 3. [Clinical use of granulocyte colony stimulating-factors (GM-CSF and G-CSF].
    Borota R, Borota J, Belić A, Gebauer E, Stefanović N.
    Med Pregl; 1997 Mar 23; 50(3-4):87-93. PubMed ID: 9229690
    [Abstract] [Full Text] [Related]

  • 4. [Hematopoietic growth factors in primary and therapy-related bone marrow insufficiency].
    Hansen B, Hippe E, Jacobsen GK, Johnsen HE.
    Ugeskr Laeger; 1992 Jun 08; 154(24):1697-702. PubMed ID: 1378668
    [Abstract] [Full Text] [Related]

  • 5. [Hematopoietic growth factors in prophylaxis and therapy of infections complications in children with neutropenia].
    Lehrnbecher T.
    Klin Padiatr; 2001 Jun 08; 213(4):212-38. PubMed ID: 11528556
    [Abstract] [Full Text] [Related]

  • 6. Hematopoietic growth factors in patients receiving intensive chemotherapy for malignant disorders: studies of granulocyte-colony stimulating factor (G-CSF), granulocyte-macrophage colony stimulating factor (GM-CSF), interleukin-3 (IL-3) and Flt-3 ligand (Flt3L).
    Bruserud O, Foss B, Petersen H.
    Eur Cytokine Netw; 2001 Jun 08; 12(2):231-8. PubMed ID: 11399510
    [Abstract] [Full Text] [Related]

  • 7. Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation.
    Lemoli RM, Fortuna A, Fogli M, Gherlinzoni F, Rosti G, Catani L, Gozzetti A, Miggiano MC, Tura S.
    Exp Hematol; 1995 Dec 08; 23(14):1520-6. PubMed ID: 8542941
    [Abstract] [Full Text] [Related]

  • 8. New perspectives in the treatment of acute myeloid leukemia by hematopoietic growth factors.
    Hiddemann W, Wörmann B, Reuter C, Schleyer E, Zühlsdorf M, Böckmann A, Büchner T.
    Semin Oncol; 1994 Dec 08; 21(6 Suppl 16):33-8. PubMed ID: 7528449
    [Abstract] [Full Text] [Related]

  • 9. The use of haemopoietic growth factors in the treatment of myelodysplastic syndromes.
    Greenberg PL, Negrin R, Nagler A.
    Cancer Surv; 1990 Dec 08; 9(1):199-212. PubMed ID: 2276114
    [Abstract] [Full Text] [Related]

  • 10. Clinical applications of human granulocyte-macrophage colony-stimulating factor.
    Sakamoto KM, Gasson JC.
    Int J Cell Cloning; 1991 Nov 08; 9(6):531-41. PubMed ID: 1770227
    [Abstract] [Full Text] [Related]

  • 11. Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy.
    Wong SF, Chan HO.
    Pharmacotherapy; 2005 Mar 08; 25(3):372-8. PubMed ID: 15843284
    [Abstract] [Full Text] [Related]

  • 12. [Hematopoietic growth factors and anti-infective respiratory defenses].
    Gagnadoux F, Diot P, Boissinot E, Lemarié E.
    Rev Mal Respir; 1997 Apr 08; 14(2):93-9. PubMed ID: 9198845
    [Abstract] [Full Text] [Related]

  • 13. Growth characteristics of marrow hematopoietic progenitor/precursor cells from patients on a phase I clinical trial with purified recombinant human granulocyte-macrophage colony-stimulating factor.
    Broxmeyer HE, Cooper S, Williams DE, Hangoc G, Gutterman JU, Vadhan-Raj S.
    Exp Hematol; 1988 Aug 08; 16(7):594-602. PubMed ID: 3260558
    [Abstract] [Full Text] [Related]

  • 14. Kinetic response of human marrow myeloid progenitor cells to in vivo treatment of patients with granulocyte colony-stimulating factor is different from the response to treatment with granulocyte-macrophage colony-stimulating factor.
    Broxmeyer HE, Benninger L, Patel SR, Benjamin RS, Vadhan-Raj S.
    Exp Hematol; 1994 Jan 08; 22(1):100-2. PubMed ID: 7506671
    [Abstract] [Full Text] [Related]

  • 15. A review of the efficacy and tolerability of recombinant haematopoietic growth factors in bone marrow transplantation.
    Barge AJ.
    Bone Marrow Transplant; 1993 Jan 08; 11 Suppl 2():1-11. PubMed ID: 8334433
    [Abstract] [Full Text] [Related]

  • 16. G-CSF and GM-CSF in clinical trials.
    Antman KH.
    Yale J Biol Med; 1990 Jan 08; 63(5):387-410. PubMed ID: 1705737
    [Abstract] [Full Text] [Related]

  • 17. [Hematopoietic growth factors in antineoplastic therapy from the therapeutic and economic aspect].
    Adam Z, Vorlícek J, Tomíska M.
    Vnitr Lek; 1993 May 08; 39(5):487-500. PubMed ID: 7688919
    [Abstract] [Full Text] [Related]

  • 18. Prospective, randomized trial of sequential interleukin-3 and granulocyte- or granulocyte-macrophage colony-stimulating factor after standard-dose chemotherapy in cancer patients.
    Palmeri S, Leonardi V, Danova M, Porta C, Ferrari S, Fincato G, Citarrella P.
    Haematologica; 1999 Nov 08; 84(11):1016-23. PubMed ID: 10553163
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Effect of stem cell factor (c-kit ligand), granulocyte-macrophage colony stimulating factor and interleukin 3 on hematopoietic progenitors in human long-term bone marrow cultures.
    Lemoli RM, Gulati SC.
    Stem Cells; 1993 Sep 08; 11(5):435-44. PubMed ID: 7694721
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.